Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
Diabetes & Metabolism Journal
;
: 529-535, 2011.
Article
in English
| WPRIM
| ID: wpr-22250
ABSTRACT
BACKGROUND:
The present study investigated the efficacy and safety of vildagliptin-metformin treatment compared to those of glimepiride-metformin treatment for type 2 diabetes.METHODS:
In a randomized, open-label, comparative study, 106 patients with type 2 diabetes were enrolled. The primary endpoint was a reduction in HbA1c from baseline and secondary endpoints included fasting plasma glucose (FPG) or 2-hour postprandial glucose (2h-PPG) reduction from baseline, as well as HbA1c responder rate and HbA1c reduction according to baseline HbA1c category.RESULTS:
Comparable HbA1c reduction was observed with a mean+/-standard deviation change from baseline to the 32-week endpoint of -0.94+/-1.15% in the vildagliptin group and -1.00+/-1.32% in the glimepiride group. A similar reduction in 2h-PPG (vildagliptin group 3.53+/-4.11 mmol/L vs. the glimepiride group 3.72+/-4.17 mmol/L) was demonstrated, and the decrements in FPG (vildagliptin group 1.54+/-2.41 mmol/L vs. glimepiride group 2.16+/-2.51 mmol/L) were not different between groups. The proportion of patients who achieved an HbA1c less than 7% at week 32 was 50.1% in the vildagliptin group and 56.0% in the glimepiride group. An average body weight gain of 2.53+/-1.21 kg in the glimepiride group was observed in contrast with the 0.23+/-0.69 kg weight gain noted in the vildagliptin group. A 10-fold lower incidence of hypoglycemia was demonstrated in the vildagliptin group, in addition to an absence of severe hypoglycemia.CONCLUSION:
Vildagliptin-metformin treatment provided blood glucose control efficacy comparable to that of glimepiride-metformin treatment and resulted in better adverse event profiles with lower risks of hypoglycemia and weight gain.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Plasma
/
Pyrrolidines
/
Sulfonylurea Compounds
/
Blood Glucose
/
Body Weight
/
Adamantane
/
Weight Gain
/
Incidence
/
Fasting
/
Diabetes Mellitus, Type 2
Type of study:
Controlled clinical trial
/
Incidence study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Diabetes & Metabolism Journal
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS